Nicholas Grund
CIK: 0001661887
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Akebia Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Feb 2, 2026AKBA
Akebia Therapeutics, Inc.
Sale(S)Direct53.6K shares at avg. $1.39$74K - Feb 2, 2026AKBA
Akebia Therapeutics, Inc.
Sale(S)Direct31.2K shares at avg. $1.39$43K - Jan 30, 2026AKBA
Akebia Therapeutics, Inc.
Award(A)Direct204K shares- - Feb 3, 2025AKBA
Akebia Therapeutics, Inc.
Sale(S)Direct55.6K shares at avg. $2.10$117K - Jan 31, 2025AKBA
Akebia Therapeutics, Inc.
Award(A)Direct194.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 2, 2026 | AKBA Akebia Therapeutics, Inc. | Sale(S) | 53,585 | $1.39 | $74,483 | Direct |
| Feb 2, 2026 | AKBA Akebia Therapeutics, Inc. | Sale(S) | 31,244 | $1.39 | $43,429 | Direct |
| Jan 30, 2026 | AKBA Akebia Therapeutics, Inc. | Award(A) | 204,000 | - | $0 | Direct |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | Sale(S) | 55,621 | $2.10 | $116,804 | Direct |
| Jan 31, 2025 | AKBA Akebia Therapeutics, Inc. | Award(A) | 194,900 | - | - | Direct |
1-5 of 5 transactions
About Grund Nicholas
Grund Nicholas (SEC CIK 0001661887) files insider reports with the SEC as Chief Commercial Officer of Akebia Therapeutics, Inc. (AKBA).
Signal8 holds 3 ownership filings by Grund Nicholas, all Form 4s, filed between Feb 4, 2025 and Feb 4, 2026. Those filings report 5 transactions, from Jan 31, 2025 to Feb 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Grund Nicholas's filings is in CAMBRIDGE, MA.
Recent filings by Grund Nicholas
Other insiders filing for Akebia Therapeutics, Inc. (AKBA)
- Butler John P., CEO and President
- Ostrowski Erik, SVP, CFO, CBO & Treasurer
- Wolf Myles, Director
- Smith Cynthia, Director
- ROGERS MICHAEL W, Director
- FRIESON RON, Director